Primary Hyperoxaluria (PH) Market 2030 by DelveInsight

1. Primary hyperoxaluria (PH) is a rare condition characterized by recurrent kidney and bladder stones. The condition often results in end stage renal disease (ESRD), which is a life-threatening condition that prevents the kidneys from filtering fluids and waste products from the body effectively. Primary hyperoxaluria results from the overproduction of a substance called oxalate. Oxalate is filtered through the kidneys and excreted as a waste product in urine, leading to abnormally high levels of this substance in urine (hyperoxaluria). DelveInsight's "Primary Hyperoxaluria Market Report 2030" report delivers an in- depth understanding of the Primary Hyperoxaluria, historical and forecasted epidemiology as well as the Primary Hyperoxaluria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Primary Hyperoxaluria market report provides current treatment practices, emerging drugs, Primary Hyperoxaluria market share of the individual therapies, current and forecasted Primary Hyperoxaluria market Size from 2017 to 2030 segmented by seven major markets. The report also covers current Primary Hyperoxaluria treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Geographies covered are:  The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan Primary Hyperoxaluria Disease Overview There are three types of primary hyperoxaluria that differ in their severity and genetic cause.

2.  In primary hyperoxaluria type 1, kidney stones typically begin to appear anytime from childhood to early adulthood, and ESRD can develop at any age.  Primary hyperoxaluria type 2 is similar to type 1, but ESRD develops later in life.  In primary hyperoxaluria type 3, affected individuals often develop kidney stones in early childhood, but few cases of this type have been described so additional signs and symptoms of this type are unclear. The DelveInsight Primary Hyperoxaluria market report gives a thorough understanding of the Primary Hyperoxaluria by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. Request for sample pages of the report: https://www.delveinsight.com/sample- request/primary-hyperoxaluria-market Primary Hyperoxaluria Epidemiology According to the National Organization for Rare Disorders, the exact incidence and prevalence of these disorders is unknown. Because some cases go undiagnosed or misdiagnosed, determining these disorders’ true frequency in the general population is difficult. The Primary Hyperoxaluria epidemiology division provide insights about historical and current Primary Hyperoxaluriapatient pool and forecasted trend for every seven major countries. Key Findings  As per the National Institutes of Health, Primary hyperoxaluria is estimated to affect 1 in 58,000 individuals worldwide.  Type 1 is the most common form, accounting for approximately 80 percent of cases.  Types 2 and 3 each account for about 10 percent of cases. Click here and view epidemiology insights of the report. Primary Hyperoxaluria (PH) Treatment Protocols The Primary Hyperoxaluria treatment is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of specialists. Pediatricians, surgeons, specialists who assess and treat problems of the kidneys (nephrologists), specialists who assess and treat problems of the liver (hepatologists),

3. specialists who assess and treat problems of the urinary tract (urologists), dieticians, and other healthcare professionals may need to systematically and comprehensively plan an affect child’s treatment. Genetic counseling may be of benefit for affected individuals and their families. Psychosocial support for the entire family is essential as well. Specific therapeutic procedures and interventions may vary, depending upon numerous factors, such as disease stage; specific subtype; responsiveness to pyridoxine; the presence or absence of certain symptoms; an individual’s age and general health; and/or other elements. Primary Hyperoxaluria Drug Chapters The Primary Hyperoxaluria current pipeline has many significant products which are being developed by key players. A few of the potential emerging therapy for Primary Hyperoxaluria include Stiripentol (Biocodex), Oxabact OC5 - Oxalobacter formigenes HC-1 (OxThera) and Lumasiran (Alnylam Pharmaceuticals) among others. The dynamics of Primary Hyperoxaluria market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also the expected launch of emerging therapies such as Stiripentol, Oxabact OC5 - Oxalobacter formigenes HC-1, Lumasiran andothers during the forecast period. Click here and view pipeline insights of the report. Primary Hyperoxaluria Market Outlook At present, there are no approved therapies for the treatment of Primary Hyperoxaluria and the current therapeutic market for Primary Hyperoxaluria is based on the therapies such as Enzyme reactivation therapy, Gene therapies and Substrate reduction therapy through RNA-interference. Other treatment options include Chemical chaperones, supplements intake, Hepatocyte transplantation, Dialysis whereas the general therapies for nephrolithiasis benefit all individuals with PH. Drugs such as thiazides and potassium citrate or neutral orthophosphates can decrease urinary calcium excretion and inhibit stone formation, respectively. According to DelveInsight, Primary Hyperoxaluria market in 7MM is expected to change in the study period 2017-2030. Key Findings

4. The United States Market Outlook EU-5 Countries: Market Outlook Japan Market Outlook Request for a free sample pages of the report: https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline- insight Visit our repository of reports: https://www.delveinsight.com/report-store.php